acy-1215 and Carcinoma--Non-Small-Cell-Lung

acy-1215 has been researched along with Carcinoma--Non-Small-Cell-Lung* in 2 studies

Other Studies

2 other study(ies) available for acy-1215 and Carcinoma--Non-Small-Cell-Lung

Article	Year
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer. Journal of medicinal chemistry, 2019, 01-24, Volume: 62, Issue:2 Topics: Acetylation; Animals; Apoptosis; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mice; Mice, Inbred C57BL; Paclitaxel; Quinazolinones; Structure-Activity Relationship; Tissue Distribution; Transplantation, Homologous; Tubulin	2019
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer discovery, 2017, Volume: 7, Issue:8 Effective therapies for non-small cell lung cancer (NSCLC) remain challenging despite an increasingly comprehensive understanding of somatically altered oncogenic pathways. It is now clear that therapeutic agents with potential to impact the tumor immune microenvironment potentiate immune-orchestrated therapeutic benefit. Herein, we evaluated the immunoregulatory properties of histone deacetylase (HDAC) and bromodomain inhibitors, two classes of drugs that modulate the epigenome, with a focus on key cell subsets that are engaged in an immune response. By evaluating human peripheral blood and NSCLC tumors, we show that the selective HDAC6 inhibitor ricolinostat promotes phenotypic changes that support enhanced T-cell activation and improved function of antigen-presenting cells. The bromodomain inhibitor JQ1 attenuated CD4 Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Male; Mice; Middle Aged; Pyrimidines; Xenograft Model Antitumor Assays	2017

Article

Year

Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.

Journal of medicinal chemistry, 2019, 01-24, Volume: 62, Issue:2

Topics: Acetylation; Animals; Apoptosis; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mice; Mice, Inbred C57BL; Paclitaxel; Quinazolinones; Structure-Activity Relationship; Tissue Distribution; Transplantation, Homologous; Tubulin

2019

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Cancer discovery, 2017, Volume: 7, Issue:8

Effective therapies for non-small cell lung cancer (NSCLC) remain challenging despite an increasingly comprehensive understanding of somatically altered oncogenic pathways. It is now clear that therapeutic agents with potential to impact the tumor immune microenvironment potentiate immune-orchestrated therapeutic benefit. Herein, we evaluated the immunoregulatory properties of histone deacetylase (HDAC) and bromodomain inhibitors, two classes of drugs that modulate the epigenome, with a focus on key cell subsets that are engaged in an immune response. By evaluating human peripheral blood and NSCLC tumors, we show that the selective HDAC6 inhibitor ricolinostat promotes phenotypic changes that support enhanced T-cell activation and improved function of antigen-presenting cells. The bromodomain inhibitor JQ1 attenuated CD4

Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Male; Mice; Middle Aged; Pyrimidines; Xenograft Model Antitumor Assays

2017